Biomarkers Market Report 2026

The biomarkers market size has grown rapidly in recent years. It will grow from $77.42 billion in 2025 to $88.42 billion in 2026 at a compound annual growth rate (CAGR) of 14.2%. The growth in the historic period can be attributed to advancements in molecular biology, growing pharmaceutical R&D spending, rising cancer prevalence, increased use in clinical trials, demand for targeted therapies.

The biomarkers market size is expected to see rapid growth in the next few years. It will grow to $150.52 billion in 2030 at a compound annual growth rate (CAGR) of 14.2%. The growth in the forecast period can be attributed to expansion of personalized treatment approaches, rising adoption of liquid biopsy biomarkers, increasing regulatory support for biomarker-based drugs, growth in neurological disease research, expanding collaborations between pharma and diagnostics firms. Major trends in the forecast period include increasing use of biomarkers in precision medicine, growing integration in drug discovery and development, rising adoption in oncology and chronic disease management, expansion of companion diagnostics, greater focus on early disease detection.

The rising prevalence of heart diseases is anticipated to drive the growth of the biomarkers market during the forecast period. The use of biomarkers in patients with heart disease has increased significantly in recent years. Currently, natriuretic peptides are the most widely used biomarkers and assist in the diagnosis of patients with heart failure. Biomarkers such as circulating markers, including high-sensitivity C-reactive protein, are also used for the diagnosis of heart failure. Heart disease remains one of the leading causes of death among most racial and ethnic groups in the United States. The growing incidence of heart diseases is expected to increase the demand for biomarkers. For example, in September 2025, according to the British Heart Foundation, a UK-based charity, more than 7.6 million people in the UK - including over 4 million men and more than 3.6 million women - were living with cardiovascular disease, and projections suggest that, driven by an aging population and improved survival rates, this number could increase by around 1 million by 2030 and by approximately 2 million by 2040. Consequently, the rise in heart diseases is fueling the growth of the biomarkers market.

Leading companies operating in the biomarker market are focusing on the development of innovative offerings such as biomarker tests to expand their customer base, boost sales, and increase revenue. Biomarker tests, also referred to as biomarker assays, are laboratory or diagnostic methods used to measure specific biological markers, including molecules, genes, proteins, or other substances, to deliver insights into various physiological or pathological processes within the body. For example, in July 2023, Quest Diagnostics, a US-based medical laboratory company, introduced a new prostate cancer biomarker test. This newly launched tissue-based testing service is designed to address the critical clinical need for tools that help differentiate potentially aggressive prostate cancer cases in men. Quest developed and validated the test through an intellectual property licensing agreement with Envision, enabling the use of Envision’s proprietary biomarker and immunohistochemistry technology, which incorporates unique staining techniques and novel biomarkers known as EV1, EV2, and EV3.

In July 2023, Biocare Medical, a US-based biotechnology company, acquired Empire Genomics for an undisclosed amount. With this acquisition, Biocare aims to expand its molecular portfolio to include more than 1 million biomarkers and to introduce rapid biomarker development to strengthen its leadership in cancer research. Biocare Medical’s enhanced molecular offerings, along with its advanced automation platforms such as the ONCORE Pro X, are expected to enable researchers to accelerate their work and speed up cancer diagnostics, leading to improved patient outcomes at an unprecedented rate. Empire Genomics is a US-based biotechnology company.

Major companies operating in the biomarkers market are Enzo Biochem Inc, Bio-Rad Laboratories Inc., Merck KGaA, PerkinElmer Inc., QIAGEN N. V., Adaptive Biotechnologies Corp., Agilent Technologies Inc., Biocrates Life Sciences AG, BioFire Diagnostics LLC, BioReference Laboratories Inc., Bio-Techne Corporation, Cepheid Inc., Eurofins Scientific SE, Exact Sciences Corporation, Foundation Medicine Inc., Genomic Health Inc., GenScript Biotech Corporation, Guardant Health Inc., Illumina Inc., Invitae Corporation, Laboratory Corporation of America Holdings, Luminex Corporation, Metabolon Inc., Myriad Genetics Inc., Natera Inc., Pacific Biosciences of California Inc., Quest Diagnostics Incorporated, Roche Diagnostics Corporation, Thermo Fisher Scientific Inc., Veracyte Inc.

North America was the largest region in the biomarkers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the biomarkers market by increasing costs for imported reagents, assay kits, analytical instruments, and laboratory consumables used in biomarker discovery and validation. These impacts are most evident across oncology and neurological biomarker segments and in regions dependent on cross-border life science imports such as Asia-Pacific and Latin America. Higher tariffs have slowed procurement cycles for research institutes and pharmaceutical companies. Conversely, tariffs are encouraging local manufacturing of diagnostic reagents and strengthening regional supply chains, supporting long-term market stability.

The biomarkers market research report is one of a series of new reports that provides biomarkers market statistics, including biomarkers industry global market size, regional shares, competitors with a biomarkers market share, detailed biomarkers market segments, market trends and opportunities, and any further data you may need to thrive in the biomarkers industry. This biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Biomarkers are biological molecules that serve as indicators of a condition, disease, or abnormal biological process and can be identified in tissues, body fluids, or blood. They are used to evaluate how effectively the body responds to the treatment of a disease or condition. Biomarkers play an important clinical role in refining and guiding treatment decisions.

The primary types of biomarkers include biomarkers of exposure and biomarkers of disease. Biomarkers of exposure are substances related to specific chemicals that can be detected in the body and help identify exposure through direct contact, inhalation, or ingestion. Various technologies applied in biomarker analysis include safety biomarkers, efficacy biomarkers, and validation biomarkers, which are used in the treatment of diseases such as neurological disorders, cancer, immunological diseases, cardiovascular diseases, and others. These biomarkers are utilized by pharmaceutical companies, government and private research organizations, academic institutions, and medical device manufacturers for applications such as risk assessment, molecular diagnostics development, disease diagnosis, drug discovery and development, drug formulation, forensic applications, and others, including DNA fingerprinting.

The biomarkers market consists of sales of molecular biomarkers, cellular biomarkers or imaging biomarkers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.